Novel vaccine carrier

A vaccine carrier and vaccine technology, applied in liposome delivery, antibody medical components, viruses/phages, etc., can solve the problems of not rising antibody titers and ineffective induction of immune responses, etc.

Inactive Publication Date: 2009-03-04
NAI
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, as mentioned above, there are problems in many immunizations in the past: the antibody titer of antibodies other than IgG antibodies (for example, IgA and IgM) does not increase, and the cellular immune response cannot be sufficiently induced. Mucosal surfaces at sites of infection with infectious pathogens are ineffective in inducing an immune response including the production of antigen-specific antibodies (secretory IgA)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel vaccine carrier
  • Novel vaccine carrier
  • Novel vaccine carrier

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Embodiment 1: the making of succinylated polyglycidol (SucPG) liposome

[0060] As liposomes containing SucPG, lipids formed to dipalmitoylphosphatidylcholine (DPPC) (Sigma) and dioleylphosphatidylethanolamine (DOPE) (Sigma) in a molar ratio of 1:1 (10 micromoles each) In the lipid combination, SucPG with a weight ratio of 10%, 20% or 30% of lipid was added to produce three kinds of SucPG-containing liposomes with different SucPG concentrations. The SucPG used in this embodiment has a n-decyl group with 10 carbon atoms as an alkyl group, which is synthesized according to the method described in the literature (KonoK. et al., J.Controlled Release, 68, 225-235 (2000 ); Kono K. et al., Biochim.Biophys.Acta (Biochemistry and Biophysics Acta), 1325, 143-154 (1997); or Kono K. et al., Biochim.Biophys.Acta (Biochemistry and Biophysics Acta ), 1193, 1-9 (1994)). Specifically, polyglycidyl acetate was prepared by reacting polyepichlorohydrin in dimethylformamide at 175°C for 6 h...

Embodiment 2

[0062] Embodiment 2: the study of the immune response when the vaccine formed by succinylated polyglycidyl (SucPG) liposomes is inoculated through the mucosa

[0063] The purpose of this embodiment is: the immune response of the vaccine formed by the liposome containing SucPG made in Example 1 when inoculated through the mucosa, and the vaccine formed by the liposome not containing SucPG are comparatively studied.

[0064] The vaccine formed by the liposome containing SucPG was prepared according to the method described in Example 1. On the other hand, as a vaccine formed from liposomes not containing SucPG, OVA was encapsulated in a lipid composition with a molar ratio of DPPC:DOPE of 1:1, thereby making multilamellar liposomes (OVA - Vaccines formed from liposomes) (MLV).

[0065] The above-mentioned OVA-SucPG-liposome-formed vaccine, the OVA-liposome-formed vaccine, and the OVA-only vaccine were inoculated to BALB / c mice in a nasal manner, separated by 7 Inoculate twice a...

Embodiment 3

[0072] Example 3: Induction of cellular immune response brought about by mucosal administration of vaccines formed by liposomes containing SucPG

[0073] In Example 2, it was shown that the use of a vaccine formed by liposomes containing SucPG, through mucosal inoculation of antigens for immunization, has the possibility of inducing a cellular immune response. Therefore, in this example, the use of liposomes containing SucPG The ability of liposomes to form a cellular immune response to vaccines was studied.

[0074] The vaccine formed by the OVA-SucPG-liposome prepared in Example 1 was inoculated nasally to BALB / c mice, and inoculated twice at intervals of 7 days, and the dosage of OVA each time was 100 μg / mouse. Seven days after the final inoculation, the mice were sacrificed, the spleens were removed, and spleen lymphocytes were purified by density gradient centrifugation.

[0075] Using TRIzol TM (Invitrogen) Total RNA was extracted from purified splenic lymphocytes, and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An object is to prepare a novel vaccine carrier which can be used in the production of a vaccine capable of inducing a humoral or cellular immune response with good efficiency. Another object is to provide a vaccine capable of inducing a humoral or cellular immune response with good efficiency. It is found that the objects can be achieved by using a liposome comprising succinylated polyglycidol. Thus, disclosed is a vaccine carrier which comprises a liposome comprising succinylated polyglycidol.

Description

technical field [0001] The present invention relates to a novel vaccine carrier using a liposome having a membrane fusogenic lipid membrane. Background technique [0002] The animal's immune system has the function of recognizing noumenon and nonnoumenon and eliminating nonnoumenon from the body. This immune response in a living body, which distinguishes itself from non-self, is carried out by cellular immunity using class I MHC (major histocompatibility complex) molecules and humoral immunity using class II MHC molecules. For example, upon infection by viruses or bacteria as infectious agents, the organism uses these cellular or humoral immunity to eliminate these infectious agents. [0003] Vaccination is often used as a preventive measure against such infectious pathogens. A very wide variety of vaccines have been utilized, both in humans and in livestock animals and pets. [0004] These vaccines are broadly classified into two types, inactivated vaccines (toxoid vacci...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61K9/127A61K39/002A61K39/005A61K39/02A61K39/085A61K39/112A61K39/35A61K47/24A61P31/04A61P33/00
CPCA61K2039/541A61K39/39A61K9/127C12N2760/18111A61K39/0241A61K9/1272A61K39/0208C12N2760/18134A61K2039/521C12N2760/18151A61K39/17A61K2039/55555A61K39/005A61K39/085A61K2039/542A61K2039/543A61K39/12A61P31/04A61P31/12A61P33/00A61P33/02A61K39/002A61K39/02A61K39/35
Inventor 渡来仁河野健司
Owner NAI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap